Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

The Vanguard Value ETF is an index fund, tracking the CRSP US Large Cap Value Index, which itself is focused on holding ...

CRSP stock opened at $37.77 on Friday. The stock has a market cap of $3.24 billion, a PE ratio of -8.64 and a beta of 1.85. The stock has a 50-day moving average price of $40.93 and a two-hundred ...

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced ...

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other ...

In trading on Tuesday, shares of CRISPR Therapeutics AG (Symbol: CRSP) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $33.05 per share. By ...

The Kenya Revenue Authority (KRA) is set to publish a new template for taxing imported second-hand cars by July this year, as ...